On February 16, 2024, 180 Life Sciences Corp. filed a prospectus supplement with the SEC, updating and amending its previous prospectus dated February 9, 2024. The supplement includes information from the company's Current Report on Form 8-K and announces shareholder approval for the issuance of shares upon exercise of certain warrants. The warrants are now exercisable until February 16, 2029. Additionally, at a Special Meeting on the same day, stockholders approved a reverse stock split, an amendment to the company's Omnibus Incentive Plan, and the issuance of shares exceeding 19.99% of the outstanding common stock at a price below the Nasdaq minimum. The company's common stock and warrants are traded on the Nasdaq under the symbols 'ATNF' and 'ATNFW' respectively. The last reported sale price of the common stock was $0.21 per share on February 15, 2024.

On February 16, 2024, 180 Life Sciences Corp. filed a prospectus supplement with the SEC, updating and amending its previous prospectus dated February 9, 2024. The supplement includes information from the company's Current Report on Form 8-K and announces shareholder approval for the issuance of shares upon exercise of certain warrants. The warrants are now exercisable until February 16, 2029. Additionally, at a Special Meeting on the same day, stockholders approved a reverse stock split, an amendment to the company's Omnibus Incentive Plan, and the issuance of shares exceeding 19.99% of the outstanding common stock at a price below the Nasdaq minimum. The company's common stock and warrants are traded on the Nasdaq under the symbols 'ATNF' and 'ATNFW' respectively. The last reported sale price of the common stock was $0.21 per share on February 15, 2024.